BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 29734195)

  • 1. Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome.
    Miller WL; Merke DP
    Horm Res Paediatr; 2018; 89(5):352-361. PubMed ID: 29734195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenascin-X haploinsufficiency associated with Ehlers-Danlos syndrome in patients with congenital adrenal hyperplasia.
    Merke DP; Chen W; Morissette R; Xu Z; Van Ryzin C; Sachdev V; Hannoush H; Shanbhag SM; Acevedo AT; Nishitani M; Arai AE; McDonnell NB
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E379-87. PubMed ID: 23284009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of serum tenascin-X in patients with congenital adrenal hyperplasia at risk for Ehlers-Danlos contiguous gene deletion syndrome CAH-X.
    Kolli V; Kim H; Rao H; Lao Q; Gaynor A; Milner JD; Merke DP
    BMC Res Notes; 2019 Oct; 12(1):711. PubMed ID: 31666125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A TNXB splice donor site variant as a cause of hypermobility type Ehlers-Danlos syndrome in patients with congenital adrenal hyperplasia.
    Lao Q; Mallappa A; Rueda Faucz F; Joyal E; Veeraraghavan P; Chen W; Merke DP
    Mol Genet Genomic Med; 2021 Feb; 9(2):e1556. PubMed ID: 33332743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ehlers-Danlos Syndrome Caused by Biallelic TNXB Variants in Patients with Congenital Adrenal Hyperplasia.
    Chen W; Perritt AF; Morissette R; Dreiling JL; Bohn MF; Mallappa A; Xu Z; Quezado M; Merke DP
    Hum Mutat; 2016 Sep; 37(9):893-7. PubMed ID: 27297501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Congenital adrenal hyperplasia with a
    Ivo CR; Fitas AL; Madureira I; Diamantino C; Gomes S; Gonçalves J; Lopes L
    J Pediatr Endocrinol Metab; 2023 Jan; 36(1):81-85. PubMed ID: 36259452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Congenital Adrenal Hyperplasia and Ehlers-Danlos Syndrome.
    Marino R; Moresco A; Perez Garrido N; Ramirez P; Belgorosky A
    Front Endocrinol (Lausanne); 2022; 13():803226. PubMed ID: 35282436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prevalence of the Chimeric TNXA/TNXB Gene and Clinical Symptoms of Ehlers-Danlos Syndrome with 21-Hydroxylase Deficiency.
    Gao Y; Lu L; Yu B; Mao J; Wang X; Nie M; Wu X
    J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32291442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadening the Spectrum of Ehlers Danlos Syndrome in Patients With Congenital Adrenal Hyperplasia.
    Morissette R; Chen W; Perritt AF; Dreiling JL; Arai AE; Sachdev V; Hannoush H; Mallappa A; Xu Z; McDonnell NB; Quezado M; Merke DP
    J Clin Endocrinol Metab; 2015 Aug; 100(8):E1143-52. PubMed ID: 26075496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAH-X Syndrome: Genetic and Clinical Profile.
    Concolino P; Falhammar H
    Mol Diagn Ther; 2022 May; 26(3):293-300. PubMed ID: 35476220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ehlers-Danlos Syndrome: Molecular and Clinical Characterization of TNXA/TNXB Chimeras in Congenital Adrenal Hyperplasia.
    Marino R; Garrido NP; Ramirez P; Notaristéfano G; Moresco A; Touzon MS; Vaiani E; Finkielstain G; Obregón MG; Balbi V; Soria I; Belgorosky A
    J Clin Endocrinol Metab; 2021 Jun; 106(7):e2789-e2802. PubMed ID: 33482002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene.
    Fanis P; Skordis N; Phylactou LA; Neocleous V
    Hormones (Athens); 2023 Mar; 22(1):71-77. PubMed ID: 36264454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The phenotypic spectrum of contiguous deletion of CYP21A2 and tenascin XB: quadricuspid aortic valve and other midline defects.
    Chen W; Kim MS; Shanbhag S; Arai A; VanRyzin C; McDonnell NB; Merke DP
    Am J Med Genet A; 2009 Dec; 149A(12):2803-8. PubMed ID: 19921645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudogene
    Lao Q; Zhou K; Parker M; Faucz FR; Merke DP
    Genes (Basel); 2023 Jan; 14(2):. PubMed ID: 36833192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elastic fiber abnormalities in hypermobility type Ehlers-Danlos syndrome patients with tenascin-X mutations.
    Zweers MC; Dean WB; van Kuppevelt TH; Bristow J; Schalkwijk J
    Clin Genet; 2005 Apr; 67(4):330-4. PubMed ID: 15733269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Throughput Screening for CYP21A1P-TNXA/TNXB Chimeric Genes Responsible for Ehlers-Danlos Syndrome in Patients with Congenital Adrenal Hyperplasia.
    Lao Q; Brookner B; Merke DP
    J Mol Diagn; 2019 Sep; 21(5):924-931. PubMed ID: 31229653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of CAH-X Syndrome in Italian Patients with Congenital Adrenal Hyperplasia (CAH) Due to 21-Hydroxylase Deficiency.
    Paragliola RM; Perrucci A; Foca L; Urbani A; Concolino P
    J Clin Med; 2022 Jul; 11(13):. PubMed ID: 35807105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenascin-X, collagen, and Ehlers-Danlos syndrome: tenascin-X gene defects can protect against adverse cardiovascular events.
    Petersen JW; Douglas JY
    Med Hypotheses; 2013 Sep; 81(3):443-7. PubMed ID: 23830591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the efficacy of a long-read sequencing-based approach in the clinical diagnosis of neonatal congenital adrenocortical hyperplasia.
    Zhang R; Cui D; Song C; Ma X; Cai N; Zhang Y; Feng M; Cao Y; Chen L; Qiang R
    Clin Chim Acta; 2024 Mar; 555():117820. PubMed ID: 38307397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis and genetic testing strategies for diagnosing 21-hydroxylase deficiency, including CAH-X syndrome.
    Kim JH; Kim GH; Yoo HW; Choi JH
    Ann Pediatr Endocrinol Metab; 2023 Jun; 28(2):77-86. PubMed ID: 37401054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.